Ironwood Pharmaceuticals, Inc. — Q2 2020 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2020. Unaudited results; dollar amounts below are in millions unless stated otherwise. Ironwood is a GI-focused company whose principal commercial product is LINZESS, marketed with AbbVie in the U.S. and through partners in other territories.
Financial performance and liquidity
| Metric | Q2 2020 | Q2 2019 | First half 2020 | First half 2019 |
|---|---|---|---|---|
| Total revenue | $89.4 | $102.2 | $169.4 | $170.9 |
| Operating income | $32.7 | $21.6 | $45.9 | $4.6 |
| Net income (loss), continuing operations | $25.2 | $12.3 | $28.5 | ($9.6) |
| Net income (loss), including discontinued operations | $25.2 | $12.3 | $28.5 | ($47.0) |
| R&D expense | $22.1 | $28.8 | $50.1 | $61.0 |
| SG&A expense | $34.6 | $43.2 | $71.1 | $92.3 |
Q2 operating margin was approximately 36.6% versus 21.1% a year earlier; first-half operating margin was approximately 27.1% versus 2.7%. The filing reports no cost of revenue in Q2 2020, compared with $11.3 million in Q2 2019; first-half cost of revenue was $2.2 million versus $12.4 million. Interest expense was $7.3 million in Q2 and $14.5 million for the first half. First-half derivative loss was $3.9 million, versus a $3.3 million gain in 2019.
Cash flow and liquidity: First-half operating cash flow was $63.7 million, compared with cash used of $63.0 million from continuing operations in 2019. Capital expenditures were $1.8 million; stock-option and employee-stock-plan proceeds were $14.4 million. Cash, cash equivalents and restricted cash increased $76.2 million to $255.5 million; unrestricted cash and equivalents were $253.3 million at June 30. Current assets were $374.3 million and current liabilities $26.7 million. Management said cash on hand was expected to support projected operating needs for at least 12 months from issuance of the statements.
Debt: Convertible notes had $520.7 million aggregate principal outstanding: $120.7 million due 2022, $200 million due 2024 and $200 million due 2026. Their balance-sheet carrying value was $418.9 million after unamortized discounts and issuance costs. Operating lease liabilities totaled $23.8 million. Stockholders’ deficit was $36.9 million.
Material changes versus prior comparable periods
- Q2 revenue declined 13% year over year, while first-half revenue declined 1%. Collaborative-arrangements revenue rose 16% in Q2 and 14% in the first half, primarily from higher U.S. LINZESS collaboration profit share, attributed to increased prescription demand and lower collaboration-related selling expenses during COVID-19.
- API sales fell sharply after Ironwood ceased supplying Astellas in Japan beginning in 2020: Q2 API revenue was nearly zero versus $24.9 million; first-half API revenue was $5.5 million versus $27.5 million. First-half 2020 included $5.5 million of API, drug-product and finished-goods sales to AstraZeneca in China.
- Lower R&D and SG&A expenses reflected reduced IW-3718 development costs, lower operating and facility costs, and the absence of 2019 separation and restructuring costs. Prior-year first-half results also included a $37.4 million loss from the sGC business, separated into Cyclerion in April 2019.
- AbbVie completed its acquisition of Allergan in May 2020; the linaclotide collaboration and license arrangements remained in effect.
Outlook, commentary and risks
- No quantitative revenue or earnings guidance is provided in the supplied filing text. Management expects LINZESS collaboration revenue to remain a significant source of revenue and substantial development and commercialization expenses to continue.
- COVID-19 limited in-person promotion and affected healthcare access. The filing says U.S. LINZESS supply had not experienced significant pandemic-related disruption as of the report date, but future demand, reimbursement, promotion and supply remain exposed.
- IW-3718 Phase III enrollment was disrupted by the pandemic. Ironwood stopped enrollment in one of two trials to conduct an early efficacy assessment; enrollment continued in the other but was slower than before COVID-19. Management reported delayed expected top-line data and anticipated increased aggregate trial expenses.
- Ironwood and AbbVie discontinued MD-7246 after its Phase II IBS-D trial failed to meet primary or key secondary endpoints.
- In January 2020, Ironwood and AbbVie settled patent litigation with Sandoz and Teva, resolving the last then-outstanding ANDA cases seeking early generic LINZESS marketing. Generic competition, future patent challenges and the durability of protection remain risks.
- Other key risks include dependence on LINZESS and AbbVie, partner execution and reporting, reimbursement and pricing pressure, clinical and regulatory uncertainty, third-party manufacturing and supply, convertible-debt obligations, and potential tax liabilities if the Cyclerion separation does not qualify as tax-free. The filing reports no material changes to previously disclosed contractual commitments.
Important facts for investors to verify
- Whether LINZESS prescription demand and collaboration profit share remain resilient as promotion, patient access and reimbursement evolve after pandemic disruptions.
- Progress and timing of the ongoing IW-3718 trial and early efficacy assessment, including any revised data expectations and trial-cost implications.
- Actual partner sales, expenses, royalty calculations and receivable collections; approximately $128.4 million of receivables related to collaboration revenue and API sales was outstanding at June 30, 2020.
- Cash generation and liquidity relative to $520.7 million of note principal, upcoming interest payments and maturities.
- Developments in generic LINZESS litigation, patent protection, and any further regulatory or commercial changes following AbbVie’s acquisition of Allergan.